Pharmacotherapy of autism and related disorders

Psychiatric Annals

Volumn 37, Issue 7, 2007, Pages 490-500

  Erickson, Craig A ^a   Posey, David J ^a   Stigler, Kimberly A ^a   Mcdougle, Christopher J ^a  

^a INDIANA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 34548040702     PISSN: 00485713     EISSN: None     Source Type: Journal    
DOI: 10.3928/00485713-20070701-03     Document Type: Review

References (50)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Press; 1994.
2. Greenhill L, Beyer DH, Finkleson J, et al. Guidelines and algorithms for the use of methylphenidate in children with attention-deficit/hyperactivity disorder. J Atten Disord. 2002;6(Suppl 1):S89-S100.
3. Campbell M. Pharmacotherapy in early infantile autism. Biol Psychiatry. 1975;10(4):399-423.
4. Aman MG. Stimulant drug effects in developmental disorders and hyperactivity-toward a resolution of disparate findings. J Autism Dev Disord. 1982;12(4):385-398.
5. Stigler KA, Desmond LA, Posey DJ, Wiegand RE, McDougle CJ. A naturalistic retrospective analysis of psychostimulants in pervasive developmental disorders. J Child Adolesc Psychopharmacol. 2004; 14(1):49-56.
6. Quintana H, Birmaher B, Sledge D, et al. Use of methylphenidate in the treatment of children with autistic disorder. J Autism Dev Disord. 1995;25(3):283-294.
7. Handen BL, Johnson CR, Lubetsky M. Efficacy of methylphenidate among children with autism and symptoms of attention-deficit hyperactivity disorder. J Autism Dev Disord. 2000;30(3):245-255.
8. Research Units on Pediatric Psychopharmacology Autism Network. Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity. Arch Gen Psychiatry. 2005;62(11): 1266-1274.
9. Posey DJ, Aman MG, McCracken JT, et al. Positive effects of methylphenidate on inattention and hyperactivity in pervasive developmental disorders: analysis of secondary measures. Biol Psychiatry. 2007;61(4):538-544.
10. Greenhill LL, Pliszka S, Dulcan MK, et al. Summary of the practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry. 2001;40(11): 1352-1315.
11. Newcorn JH, Schulz K, Harrison M, DelBellis MD, Udarbe JK, Halperin JM. Alpha-2 adrenergic agonists: neurochemistry, efficacy, and clinical guidelines for use in children. J Child Adolesc Psychopharmacol. 1998;45(5);1099-1122.
12. Jaselskis CA, Cook Jr. EH, Fletcher KE, Leventhal BL. Clonidine treatment of hyperactive and impulsive children with autistic disorder. J Clin Psychopharmacol. 1992;12(5):322-327.
13. Fankhauser MP, Karumanchi VC, German ML, Yates A, Karumanchi SD. A double-blind, placebo-controlled study of the efficacy of transdermal clonidine in autism. J Clin Psychiatry. 1992;53(3);77-82.
14. Posey DJ, Puntney JI, Sasher TM, Kem DL, McDougle CJ. Guanfacine treatment of hyperactivity and inattention in pervasive developmental disorders: a retrospective analysis of 80 cases. J Child Adolesc Psychopharmacol. 2004;14(2):233-241.
15. Scahill L, Aman MG, McDougle CJ, et al. A prospective open trial of guanfacine in children with pervasive developmental disorders. J Child Adolesc Psychopharmacol. 2006;16(5);589-598.
16. Posey DJ, Wiegand RE, Wilkerson J, Maynard M, Stigler KA, McDougle CJ. Openlabel atomoxetine for attention-deficit/hyperactivity disorder symptoms associated with high-functioning pervasive development disorder. J Child Adolesc Psychopharmacol. 2006;16(5):599-610.
17. Troost PW, Steenhuis MP, Tuynman-Qua HG, et al. Atomoxetine for attention deficit/ hyperactivity disorder symptoms in children with pervasive developmental disorders: a pilot study. J Child Adolesc Psychopharmacol. 2006;16(5):611-619.
18. Arnold LE, Aman MG, Cook AM, et al. Atomoxetine for hyperactivity in autism spectrum disorder: placebo-controlled crossover pilot trial. J Am Acad Child Adolesc Psychiatry. 2006;45(10):1196-1205.
19. Hellings JA, Weckbaugh M, Nickel EJ, et al. A double-blind, placebo-controlled study of valproate for aggression in youth with pervasive developmental disorders. J Am Acad Child Adolesc Psychopharmacol. 2005;15(4):682-692.
20. Anderson LT, Campbell M, Grega DM, Perry R, Small AM, Green WH. Haloperidol in the treatment of infantile autism: effects on learning and behavioral symptoms. Am J Psychiatry. 1984;141(10).1195-1202.
21. Anderson LT, Campbell M, Adams P, Small AM, Perry R, Shell J. The effects of haloperidol on discrimination learning and behavioral symptoms in autistic children. J Autism Dev Disord. 1989;19(2):227-239.
22. Campbell M, Anderson LT, Meier M, et al. A comparison of haloperidol and behavior therapy and their interaction in autistic children. J Am Acad Child Adolesc Psychiatry. 1978;17(4):640-655.
23. Cohen IL, Campbell M, Posner D, Small AM, Triebel D, Anderson JT. Behavioral effects of haloperidol in young autistic children: an objective analysis using a within-subjects reversal design. J Am Acad Child Adolesc Psychiatry. 1980;19(4):665-677.
24. Perry R, Campbell M, Adams P, et al. Long term efficacy of haloperidol in autistic children: continuous versus discontinuous drug administration. J Amer Acad Child Adolesc Psychiatry. 1989;28(1):87-92.
25. Erickson CA, Stigler KA, Posey DJ, McDougle CJ. Psychopharmacology. In: Volkmar FR, ed. Autism and Pervasive Developmental Disorder, 2nd ed. Cambridge University Press; 2007: in press.
26. McDougle CJ, Holmes JP, Carlson DC, Pelton GH, Cohen DJ, Price LH. A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders. Arch Gen Psychiatry. 1998;55(7):633-641.
27. Research Units on Pediatric Psychopharmacology (RUPP) Autism Network. Risperidone in children with autism and serious behavioral problems. N Engl J Med. 2002;347(5);314-321.
28. Shea S, Turgay A, Carroll A, et al. Risperidone treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics. 2004;114(5):e634-641.
29. Research Units on Pediatric Psychopharmacology Autism Network. Risperidone treatment of autistic disorder: longer-term benefits and blinded discontinuation after six months. Am J Psychiatry. 2005;162(7):1361-1369.
30. Malone RP, Cater J, Sheikh RM, Choudhury MS, Delaney MA. Olanzapine verus haloperidol in children with autistic disorder: an open pilot study. J Am Acad Child Adolesc Psychiatry. 2001;40(8):887-894.
31. Hollander E, Wasserman S, Swanson EN, et al. A double-blind, placebo-controlled pilot study of olanzapine in childhood/adolescent pervasive developmental disorders. J Child Adolesc Psychopharmacol. 2006;16(5):541-548.
32. Martin A, Koenig K, Scahill L, Bregman J. Open-label quetiapine in the treatment of children and adolescents with autistic disorder. J Child Adolesc Psychopharmacol. 1999;9(2):99-107.
33. Corson AH, Barkenbus JE, Posey DJ, Stigler KA, McDougle CJ. A retrospective analysis of quetiapine in the treatment of pervasive developmental disorders. J Clin Psychiatry. 2004;65(11):1531-1536.
34. McDougle CJ, Kem DL, Posey DJ. Case series: use of ziprasidone for maladaptive symptoms in youths with autism. J Am Acad Child Adolesc Psychiatry. 2002;41(8):921-927.
35. Psychopharmacological Drugs Advisory Committee. FDA background Document on Zeldox (PDAC 0700.M01). Rockvilie, MD. Food and Drug Administration. 2000.
36. Stigler KA, Posey DJ, McDougle CJ. Aripiprazole for maladaptive behavior in pervasive developmental disorders. J Child Adolesc Psychopharmacol. 2004;14(4):455-463.
37. Stigler KA, Diener JT, Kohn AE, et al. A prospective, open-label study of aripiprazole in youth with Asperger's disorder and pervasive developmental disorder not otherwise specified. Presented at: American Academy of Child and Adolescent Psychiatry Annual Meeting. October 28, 2006; San Diego, California.
38. Stigler KA, Potenza MN, Posey DJ, McDougle CJ. Weight gain associated with atypical antipsychotic use in children and adolescents: prevalence, clinical relevance, and management. Paediatr Drugs. 2004;6(1):33-14.
39. Klein DJ, Cottingham EM, Sorter M, et al. A randomized, double-blind, placebo-controlled trial of metformin treatment of weight gain associated with initiation of atypical antipsychotic therapy in children and adolescents. Am J Psychiatry. 2006;163(12):2072-2079.
40. Gordon CT, State RC, Nelson JE, et al. A double-blind comparison of clomipramine, desipramine, and placebo in the treatment of autistic disorder. Arch Gen Psychiatry. 1993:50(6):441-447.
41. Remington G, Sloman L, Konstantareas M, Parker K, Gow R. Clomipramine versus haloperidol in the treatment of autistic disorder: a double-blind, placebo-controlled, crossover study. J Clin Psychopharmacol. 2001;21(4):440-444.
42. McDougle CJ, Naylor ST, Cohen DJ, Volkmar FR, Heninger GR, Price LH. A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder. Arch Gen Psychiatry. 1996;53(11):1001-1008.
43. McDougle CJ, Kresch LE, Posey DJ. Repetitive thoughts and behavior in pervasive developmental disorders: treatment with serotonin reuptake inhibitors. J Autism Dev Disord. 2000;30(5):427-435.
44. Sugie Y, Sugie H, Fukuda T. Clinical efficacy of fluvoxamine and functional polymorphism in a serotonin transporter gene on childhood autism. J Autism Dev Disord. 2005;35(3):377-385.
45. Buchsbaum MS, Hollander E, Haznedar MM, et al. Effect of fluoxetine on regional cerebral metabolism in autistic spectrum disorders: a pilot study. Int J Neuropsychopharmacol. 2001;4(2):119-125.
46. Hollander E, Phillips A, Chaplin W, et al. A placebo controlled crossover trial of liquid fluoxetine on repetitive behaviors in childhood and adolescent autism. Neuropsychopharmacology. 2005;30(3):582-589.
47. McDougle CJ, Stigler KA, Erickson CA, Posey DJ. Pharmacology of autism. Clinical Neuroscience Research. 2006;6(3): 179-188.
48. Belsito KM, Law PA, Kirk KS, Landa RJ, Zimmerman AW. Lamotrigine therapy for autistic disorder: a randomized double-blind, placebo-controlled trial. J Autism Dev Disord. 2001;31(2):175-181.
49. King BH, Wright DM, Handen BL, et al. Double-blind, placebo-controlled study of amantadine hydrochloride in the treatment of children with autistic disorder. J Am Acad Child Adolesc Psychiatry. 2001;40(6):658-665.
50. Posey DJ, Kem DL, Swiezy NB, et al. A pilot study of D-cycloserine in subjects with autistic disorder. Am J Psychiatry. 2004;161(11):2115-2117.